Pengalaman Religius dalam Meditasi Transendental

This study tries to identify and analyse two types of thought, i.e. Western (Psychologists) and Islam thought (Sufist) in dealing with the phenomena of Religius experience. According to William James Religius experience is the experience of feeling close to something sacred. These experiences occur directly and emergent, but lead to the strenghthening of religioun and faith to the Creator. In the other hand, in Tasauf, the Religius experience is an esoteric experience or mystical experience. These experiences can be found through the Tarekat namely dzikir or muraqabah, in Psychology named Transendental Meditation. This method aims to strenghthen faith in the real aqidah and moral purity. In Psychology, the Religius experience which is gained in all religion teaching has many psychological dynamics: the object of the mind, stimulating, and positive perception of the sacred. Therefor, these dynamics will produce the spiritual health for those who d

The Geographic Structure of Milk Hauling Cost and Efficiencies in New York State

R.B. 94-03A survey of the milk haulers in the Northeast was conducted in June 1992 to assess the status of the industry. Detailed information on characteristics of the hauling businesses as well as the equipment operated was collected. Data submitted by milk haulers with New York addresses was isolated from the survey data set and analyzed on a regional basis. Some of the general topics addressed include the number, size, and location of hauling businesses, wages paid to hired drivers, and the cost of milk hauling equipment. A section is devoted to measures of hauling efficiency. Two sections review the costs involved in milk hauling, the first of which is more general in its approach. The second cost-based section investigates differences in hauling costs between small-and large-sized milk haulers

The Determination of Nuclear Level Densities from Experimental Information -

A novel Information Theory based method for determining the density of states from prior information is presented. The energy dependence of the density of states is determined from the observed number of states per energy interval and model calculations suggest that the method is sufficiently reliable to calculate the thermal properties of nuclei over a reasonable temperature range.Comment: 7 pages + 6 eps figures, REVTEX 3.

Long-term prognosis of epilepsy, prognostic patterns and drug resistance: a population-based study

BACKGROUND AND PURPOSE: Seizures in most people with epilepsy remit but prognostic markers are poorly understood. There is also little information on the long-term outcome of people who fail to achieve seizure control despite the use of two antiepileptic drugs (drug resistance). METHODS: People with a validated diagnosis of epilepsy in whom two antiepileptic drugs had failed were identified from primary care records. All were registered with one of 123 family physicians in an area of northern Italy. Remission (uninterrupted seizure freedom lasting 2 years or longer) and prognostic patterns (early remission, late remission, remission followed by relapse, no remission) were determined. RESULTS: In all, 747 individuals (381 men), aged 11 months to 94 years, were followed for 11 045.5 person-years. 428 (59%) were seizure-free. The probability of achieving 2-year remission was 18% at treatment start, 34% at 2 years, 45% at 5, 52% at 10 and 67% at 20 years (terminal remission, 60%). Epilepsy syndrome and drug resistance were the only independent predictors of 2- and 5-year remission. Early remission was seen in 101 people (19%), late remission in 175 (33%), remission followed by relapse in 85 (16%) and no remission in 166 (32%). Treatment response was the only variable associated with differing prognostic patterns. CONCLUSION: The long-term prognosis of epilepsy is favourable in most cases. Early seizure remission is not invariably followed by terminal remission and seizure outcome varies according to well-defined patterns. Prolonged seizure remission and prognostic patterns can be predicted by broad syndromic categories and the failure of two antiepileptic drugs

Continuum corrections to the level density and its dependence on excitation energy, n-p asymmetry, and deformation

In the independent-particle model, the nuclear level density is determined from the neutron and proton single-particle level densities. The single-particle level density for the positive-energy continuum levels is important at high excitation energies for stable nuclei and at all excitation energies for nuclei near the drip lines. This single-particle level density is subdivided into compound-nucleus and gas components. Two methods were considered for this subdivision. First in the subtraction method, the single-particle level density is determined from the scattering phase shifts. In the Gamov method, only the narrow Gamov states or resonances are included. The level densities calculated with these two methods are similar, both can be approximated by the backshifted Fermi-gas expression with level-density parameters that are dependent on A, but with very little dependence on the neutron or proton richness of the nucleus. However, a small decrease in the level-density parameter was predicted for some nuclei very close to the drip lines. The largest difference between the calculations using the two methods was the deformation dependence on the level density. The Gamov method predicts a very strong peaking of the level density at sphericity for high excitation energies. This leads to a suppression of deformed configurations and, consequently, the fission rate predicted by the statistical model is reduced in the Gamov method.Comment: 18 pages 24 figure

Modelling radiation-induced cell cycle delays

Ionizing radiation is known to delay the cell cycle progression. In particular after particle exposure significant delays have been observed and it has been shown that the extent of delay affects the expression of damage such as chromosome aberrations. Thus, to predict how cells respond to ionizing radiation and to derive reliable estimates of radiation risks, information about radiation-induced cell cycle perturbations is required. In the present study we describe and apply a method for retrieval of information about the time-course of all cell cycle phases from experimental data on the mitotic index only. We study the progression of mammalian cells through the cell cycle after exposure. The analysis reveals a prolonged block of damaged cells in the G2 phase. Furthermore, by performing an error analysis on simulated data valuable information for the design of experimental studies has been obtained. The analysis showed that the number of cells analyzed in an experimental sample should be at least 100 to obtain a relative error less than 20%.Comment: 19 pages, 11 figures, accepted for publication in Radiation and Environmental Biophysic

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

BackgroundInternal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia has been limited by rapid generation of resistance mutations, particularly in codon Asp835 (D835). We aimed to assess the highly selective oral FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukaemia.MethodsIn this phase 1-2 trial, we enrolled patients aged 18 years or older with acute myeloid leukaemia who either were refractory to induction therapy or had relapsed after achieving remission with previous treatment. Patients were enrolled into one of seven dose-escalation or dose-expansion cohorts assigned to receive once-daily doses of oral gilteritinib (20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg). Cohort expansion was based on safety and tolerability, FLT3 inhibition in correlative assays, and antileukaemic activity. Although the presence of an FLT3 mutation was not an inclusion criterion, we required ten or more patients with locally confirmed FLT3 mutations (FLT3mut+) to be enrolled in expansion cohorts at each dose level. On the basis of emerging findings, we further expanded the 120 mg and 200 mg dose cohorts to include FLT3mut+ patients only. The primary endpoints were the safety, tolerability, and pharmacokinetics of gilteritinib. Safety and tolerability were assessed in the safety analysis set (all patients who received at least one dose of gilteritinib). Responses were assessed in the full analysis set (all patients who received at least one dose of study drug and who had at least one datapoint post-treatment). Pharmacokinetics were assessed in a subset of the safety analysis set for which sufficient data for concentrations of gilteritinib in plasma were available to enable derivation of one or more pharmacokinetic variables. This study is registered with ClinicalTrials.gov, number NCT02014558, and is ongoing.FindingsBetween Oct 15, 2013, and Aug 27, 2015, 252 adults with relapsed or refractory acute myeloid leukaemia received oral gilteritinib once daily in one of seven dose-escalation (n=23) or dose-expansion (n=229) cohorts. Gilteritinib was well tolerated; the maximum tolerated dose was established as 300 mg/day when two of three patients enrolled in the 450 mg dose-escalation cohort had two dose-limiting toxicities (grade 3 diarrhoea and grade 3 elevated aspartate aminotransferase). The most common grade 3-4 adverse events irrespective of relation to treatment were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]), thrombocytopenia (33 [13%]), sepsis (28 [11%]), and pneumonia (27 [11%]). Commonly reported treatment-related adverse events were diarrhoea (92 [37%] of 252]), anaemia (86 [34%]), fatigue (83 [33%]), elevated aspartate aminotransferase (65 [26%]), and increased alanine aminotransferase (47 [19%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (98 [39%] of 252; five related to treatment), progressive disease (43 [17%]), sepsis (36 [14%]; two related to treatment), pneumonia (27 [11%]), acute renal failure (25 [10%]; five related to treatment), pyrexia (21 [8%]; three related to treatment), bacteraemia (14 [6%]; one related to treatment), and respiratory failure (14 [6%]). 95 people died in the safety analysis set, of which seven deaths were judged possibly or probably related to treatment (pulmonary embolism [200 mg/day], respiratory failure [120 mg/day], haemoptysis [80 mg/day], intracranial haemorrhage [20 mg/day], ventricular fibrillation [120 mg/day], septic shock [80 mg/day], and neutropenia [120 mg/day]). An exposure-related increase in inhibition of FLT3 phosphorylation was noted with increasing concentrations in plasma of gilteritinib. In-vivo inhibition of FLT3 phosphorylation occurred at all dose levels. At least 90% of FLT3 phosphorylation inhibition was seen by day 8 in most patients receiving a daily dose of 80 mg or higher. 100 (40%) of 249 patients in the full analysis set achieved a response, with 19 (8%) achieving complete remission, ten (4%) complete remission with incomplete platelet recovery, 46 (18%) complete remission with incomplete haematological recovery, and 25 (10%) partial remission INTERPRETATION: Gilteritinib had a favourable safety profile and showed consistent FLT3 inhibition in patients with relapsed or refractory acute myeloid leukaemia. These findings confirm that FLT3 is a high-value target for treatment of relapsed or refractory acute myeloid leukaemia; based on activity data, gilteritinib at 120 mg/day is being tested in phase 3 trials.FundingAstellas Pharma, National Cancer Institute (Leukemia Specialized Program of Research Excellence grant), Associazione Italiana Ricerca sul Cancro

High-resolution calcareous nannofossil biostratigraphy across the Toarcian Oceanic Anoxic Event in northern Italy: clues from the Sogno and Gajum Cores (Lombardy Basin, Southern Alps)

Calcareous nannofossil biostratigraphy was conducted across the toarcian oceanic anoxic event (t-oae) interval cored at Colle di Sogno and Gajum in the lombardy basin (Southern alps, northern italy). Drilling at both sites resulted in 100% recovery of unweathered material. the Sogno and Gajum Cores consist of pelagic marly limestones, marlstone, marly claystone, and a relatively expanded black shale interval named fish level considered the lithostratigraphic record of the t-oae at regional scale.Semiquantitative analyses of calcareous nannofloras allowed to achieve a high-resolution biostratigraphy of the latest Pliensbachian-early toarcian time interval. Several nannofossil biohorizons were detected, including zonal/subzonal markers and additional events related to changes in abundance. the nannofossil biostratigraphic correlation of the Sogno and Gajum Cores indicates that, according to their paleogeographic settings, the succession recovered in the Sogno Core deposited on a pelagic plateau is continuous while a hiatus of ~600 kyrs was detected in the lower-most toarcian in the Gajum Core located on a slope of a structural high.the nJt 5 and nJt 6 Zones of the standard nannofossil zonation for the Mediterranean Province were identified in both the Sogno and Gajum Cores. Our findings allow an implementation of the reference biozonation with the separation of the nJt 6a and nJt 6b Subzones, and age revision of some secondary events. the zonation established for the Lusitanian Basin (Portugal) is only partially reproducible in the Lombardy Basin, confirming nan-noplankton paleoprovincialism during the early Jurassic requiring different zonal schemes in various areas. neverthe-less, we underline that the t-oae is unambiguously constrained by the fo of C. superbus crassus and the lo of M. jansae at supra-regional scale

Structural and dynamics studies of a truncated variant of CI repressor from bacteriophage TP901-1

International audienceThe CI repressor from the temperate bacteriophage TP901-1 consists of two folded domains, an N-terminal helix-turn-helix DNA-binding domain (NTD) and a C-terminal oligomerization domain (CTD), which we here suggest to be further divided into CTD1 and CTD2. Full-length CI is a hexameric protein, whereas a truncated version, CI∆58, forms dimers. We identify the dimerization region of CI∆58 as CTD1 and determine its secondary structure to be helical both within the context of CI∆58 and in isolation. To our knowledge this is the first time that a helical dimerization domain has been found in a phage repressor. We also precisely determine the length of the flexible linker connecting the NTD to the CTD. Using electrophoretic mobility shift assays and native mass spectrometry, we show that CI∆58 interacts with the OL operator site as one dimer bound to both half-sites, and with much higher affinity than the isolated NTD domain thus demonstrating cooperativity between the two DNA binding domains. Finally, using small angle X-ray scattering data and state-of-the-art ensemble selection techniques, we delineate the conformational space sampled by CI∆58 in solution, and we discuss the possible role that the dynamics play in CI-repressor function

A Measurement of the Ds+ Lifetime

A high statistics measurement of the Ds+ lifetime from the Fermilab fixed-target FOCUS photoproduction experiment is presented. We describe the analysis of the two decay modes, Ds+ -> phi(1020)pi+ and Ds+ -> \bar{K}*(892)0K+, used for the measurement. The measured lifetime is 507.4 +/- 5.5 (stat.) +/- 5.1 (syst.) fs using 8961 +/- 105 Ds+ -> phi(1020)pi+ and 4680 +/- 90 Ds+ -> \bar{K}*(892)0K+ decays. This is a significant improvement over the present world average.Comment: 5 pages, 3 figures, 2 tables, submitted to PR